PD 117519 CAS 96392-15-3

Introduction：Basic information about PD 117519 CAS 96392-15-3, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

PD 117519 Basic information

• Product Name: PD 117519
• Synonyms: (R)-N-(2,3-Dihydro-1H-indenyl)adenosine;N-[(1R)-Indan-1-yl]adenosine;N-[[(R)-2,3-Dihydro-1H-inden]-1α-yl]adenosine;CI 947;N-[(1R)-2,3-Dihydro-1H-inden-1-yl]adenosine;PD 117519;N-[(R)-Indan-1-yl]adenosine;Adenosine, N-[(1R)-2,3-dihydro-1H-inden-1-yl]-
• CAS: 96392-15-3
• MF: C19H21N5O4
• MW: 383.4
• Product Categories: Bases & Related Reagents;Carbohydrates & Derivatives;Intermediates & Fine Chemicals;Nucleotides;Pharmaceuticals
• Mol File: 96392-15-3.mol

PD 117519 Chemical Properties

• storage temp.: 2-8°C
• solubility: DMF: 10mg/mL; DMF:PBS (pH 7.2) (1:4): 0.2mg/mL; DMSO: 5mg/mL; Ethanol: 0.1mg/mL
• form: A solid
• color: White to off-white
• InChIKey: FSKMJUWPFLDDRS-BYMDKACISA-N
• SMILES: OC[C@H]1O[C@@H](N2C3C(=C(N=CN=3)N[C@H]3C4=C(C=CC=C4)CC3)N=C2)[C@H](O)[C@@H]1O

PD 117519 Usage And Synthesis

Uses

N6-Substituted adenosine receptor agonist; a potential antihypertensive agent.

in vitro

PD 117519 (2-10 mg/kg; oral administration; 16-24 hours; male beagle dogs) treatment produces significant hemodynamic changes at Tmax (4 hours) follows by acute coronary vascular injury that is evident at 16 hours postdosing.Treatment with 2 or 10 mg/kg of PD 117519 produces significant increases in mean heart rate and decreases in mean indirectsystolic blood pressure at time of highest drug exposure, 4 hours postdosing.

in vivo

PD 117519 (2-10 mg/kg; oral administration; 16-24 hours; male beagle dogs) treatment produces significant hemodynamic changes at T_max (4 hours) follows by acute coronary vascular injury that is evident at 16 hours postdosing.Treatment with 2 or 10 mg/kg of PD 117519 produces significant increases in mean heart rate and decreases in mean indirectsystolic blood pressure at time of highest drug exposure, 4 hours postdosing^[3].

• Animal Model: 24 male beagle dogs (8-12 months old)^[3]
• Dosage: 2 mg/kg or 10 mg/kg
• Administration: Oral administration; 16 hours and 24 hours
• Result: Increased in mean heart rate and decreased in mean indirectsystolic blood pressure at time of highest drug exposure. Induced acute coronary arteriopathy. The endothelium also appears injured.